ReviewEuroasian journal of hepato-gastroenterology
Preventive and Therapeutic Vaccination for COVID-19 Using NASVAC.
Review in Euroasian journal of hepato-gastroenterology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims and background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which belongs to the coronavirus family, suddenly emerged in China and neighboring regions towards the end of 2019. It disrupted the entire world within weeks to months, and finally became a pandemic that continued for about 3 years. Patients and methods: One year after the commencement of infection, a vaccine surfaced on a global basis that imparted its effect on the progression of the infection. At the same time, symptomatic treatment was initiated to treat the patients and prevent progression to severe forms. Subsequently, antiviral drugs of different paradigms were used with mixed outcomes. Finally, immune modulators were mainly used to delay complications and reduce mortality. Results: Despite all these approaches, there have been nearly one billion infections and almost one million fatalities due to the pandemic of COVID-19. Two years after the containment of the virus, if the entire episode is considered holistically, it becomes evident that more insights are required to develop preventive and therapeutic measures against the sudden appearance of some microbe. Conclusion: This is the initial theological approach, and more sophisticated drugs may be developed based on this principle.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.